BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 31141909)

  • 1. Effect of Peritoneal Dialysis on Serum Fibrosis Biomarkers in Patients with Refractory Congestive Heart Failure.
    Kunin M; Carmon V; Beckerman P; Dinour D
    Int J Mol Sci; 2019 May; 20(11):. PubMed ID: 31141909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating matrix metalloproteinases 1, 2, 9 and their inhibitors TIMP-1 and TIMP-2 as serum markers of liver fibrosis in patients with chronic hepatitis C: comparison with PIIINP and hyaluronic acid.
    Leroy V; Monier F; Bottari S; Trocme C; Sturm N; Hilleret MN; Morel F; Zarski JP
    Am J Gastroenterol; 2004 Feb; 99(2):271-9. PubMed ID: 15046217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloproteinase-9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure.
    George J; Patal S; Wexler D; Roth A; Sheps D; Keren G
    Am Heart J; 2005 Sep; 150(3):484-7. PubMed ID: 16169329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TIMP-1, MMP-2, MMP-9, and PIIINP as serum markers for skin fibrosis in patients following severe burn trauma.
    Ulrich D; Noah EM; von Heimburg D; Pallua N
    Plast Reconstr Surg; 2003 Apr; 111(4):1423-31. PubMed ID: 12618601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum markers of deranged myocardial collagen turnover: their relation to malignant ventricular arrhythmias in cardioverter-defibrillator recipients with heart failure.
    Flevari P; Theodorakis G; Leftheriotis D; Kroupis C; Kolokathis F; Dima K; Anastasiou-Nana M; Kremastinos D
    Am Heart J; 2012 Oct; 164(4):530-7. PubMed ID: 23067911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators.
    Zannad F; Alla F; Dousset B; Perez A; Pitt B
    Circulation; 2000 Nov; 102(22):2700-6. PubMed ID: 11094035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of collagen turnover biomarkers in cardiac resynchronization therapy: A subanalysis of the TRUST CRT randomized trial population.
    Sokal A; Lenarczyk R; Kowalski O; Mitrega K; Pluta S; Stabryla-Deska J; Streb W; Urbanik Z; Krzeminski TF; Kalarus Z
    Heart Rhythm; 2016 May; 13(5):1088-1095. PubMed ID: 26776557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Collagen turnover biomarkers and systemic right ventricle remodeling in adults with previous atrial switch procedure for transposition of the great arteries.
    Lipczyńska M; Szymański P; Kumor M; Klisiewicz A; Hoffman P
    PLoS One; 2017; 12(8):e0180629. PubMed ID: 28767656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship of circulating matrix biomarkers to myocardial matrix metabolism in advanced heart failure.
    Kaye DM; Khammy O; Mariani J; Maeder MT
    Eur J Heart Fail; 2013 Mar; 15(3):292-8. PubMed ID: 23143794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Circulating Tissue Inhibitor of Metalloproteinases-1 and Procollagen Type III Aminoterminal Peptide Levels With Incident Heart Failure and Chronic Kidney Disease.
    Lieb W; Song RJ; Xanthakis V; Vasan RS
    J Am Heart Assoc; 2019 Apr; 8(7):e011426. PubMed ID: 30890055
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differences in biomarkers in patients with heart failure with a reduced vs a preserved left ventricular ejection fraction.
    de Denus S; Lavoie J; Ducharme A; O'Meara E; Racine N; Sirois MG; Neagoe PE; Zhu L; Rouleau JL; White M
    Can J Cardiol; 2012; 28(1):62-8. PubMed ID: 22104539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of adipocytokines and extracellular matrix activity in heart failure patients with high B-type natriuretic peptide.
    Ho YL; Lin YH; Lee CM; Hsu RB; Ting HT; Chou NK; Chao CL; Wang SS; Hsu HC; Chen MF
    Clin Biochem; 2009 Sep; 42(13-14):1407-12. PubMed ID: 19560452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights from the CARE-HF (Cardiac Resynchronization in Heart Failure) trial.
    Lopez-Andrès N; Rossignol P; Iraqi W; Fay R; Nuée J; Ghio S; Cleland JG; Zannad F; Lacolley P
    Eur J Heart Fail; 2012 Jan; 14(1):74-81. PubMed ID: 22089058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Matrix metalloproteinases, tissue inhibitors of metalloproteinases, aminoterminal propeptide of procollagen type III, and hyaluronan in sera and tissue of patients with capsular contracture after augmentation with Trilucent breast implants.
    Ulrich D; Lichtenegger F; Eblenkamp M; Repper D; Pallua N
    Plast Reconstr Surg; 2004 Jul; 114(1):229-36. PubMed ID: 15220598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison the prognostic value of galectin-3 and serum markers of cardiac extracellular matrix turnover in patients with chronic systolic heart failure.
    Chang YY; Chen A; Wu XM; Hsu TP; Liu LY; Chen YH; Wu YW; Lin HJ; Hsu RB; Lee CM; Wang SS; Lo MT; Chen MF; Lin YH
    Int J Med Sci; 2014; 11(11):1098-106. PubMed ID: 25170292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term statin therapy in patients with systolic heart failure and normal cholesterol: effects on elevated serum markers of collagen turnover, inflammation, and B-type natriuretic peptide.
    Abulhul E; McDonald K; Martos R; Phelan D; Spiers JP; Hennessy M; Baugh J; Watson C; O'Loughlin C; Ledwidge M
    Clin Ther; 2012 Jan; 34(1):91-100. PubMed ID: 22154198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating collagen biomarkers as indicators of disease severity in pulmonary arterial hypertension.
    Safdar Z; Tamez E; Chan W; Arya B; Ge Y; Deswal A; Bozkurt B; Frost A; Entman M
    JACC Heart Fail; 2014 Aug; 2(4):412-21. PubMed ID: 25023820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in serum tissue inhibitor of matrix metalloproteinase-1 after interferon alpha treatment in chronic hepatitis C.
    Mitsuda A; Suou T; Ikuta Y; Kawasaki H
    J Hepatol; 2000 Apr; 32(4):666-72. PubMed ID: 10782917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Longitudinal evaluation of a fibrosis index combining MMP-1 and PIIINP compared with MMP-9, TIMP-1 and hyaluronic acid in patients with chronic hepatitis C treated by interferon-alpha and ribavirin.
    Trocme C; Leroy V; Sturm N; Hilleret MN; Bottari S; Morel F; Zarski JP
    J Viral Hepat; 2006 Oct; 13(10):643-51. PubMed ID: 16970595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Independent and additional prognostic value of aminoterminal propeptide of type III procollagen circulating levels in patients with chronic heart failure.
    Cicoira M; Rossi A; Bonapace S; Zanolla L; Golia G; Franceschini L; Caruso B; Marino PN; Zardini P
    J Card Fail; 2004 Oct; 10(5):403-11. PubMed ID: 15470651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.